TON - August 2022 Vol 15, No 4

Miami Cancer Institute at Baptist Health South Florida offers patients with cancer cutting-edge, personalized therapy as well as a myriad of comprehensive services. Read More ›

The theme for the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting selected by 2021-2022 ASCO President Everett E. Vokes, MD, John E. Ultmann Professor of Medicine, and Chair, Department of Medicine, University of Chicago Duchossois Center for Advanced Medicine, Hyde Park, was advancing equitable cancer care through innovation. Read More ›

Targeting HER2 with the antibody–drug conjugate fam-trastuzumab deruxtecan-nxki (Enhertu; T-DXd) provided clinically meaningful benefits for patients with HER2-low metastatic breast cancer, according to findings presented at the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›

The number of cancer survivors continues to increase in the United States, which can be attributed to a growing and aging population, as well as recent advances in diagnosis and treatment. Read More ›

From the Editor August 2022
In the August issue of The Oncology Nurse-APN/PA (TON), we feature a variety of articles aimed at informing and empowering nurses, navigators, and advanced practice providers who work to improve the lives of patients with cancer. Read More ›

It is estimated that 14,100 new cases of cervical cancer will be diagnosed in the United States in 2022. Read More ›

First-line treatment with dostarlimab-gxly (Jemperli), a PD-1 inhibitor, achieved complete responses (CRs) in 100% of a subset of patients with locally advanced mismatch repair-deficient (dMMR) rectal cancer, sparing them surgery, chemotherapy, and radiation, as of the latest follow-up. Read More ›

Combining the PARP inhibitor olaparib (Lynparza) with abir­aterone acetate (Zytiga) led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival (PFS) versus abiraterone alone in patients with metastatic castration-resistant prostate cancer (mCRPC), regardless of homologous recombination repair (HRR) status, according to results of the phase 3 PROpel trial, presented at the 2022 American Society of Clinical Oncology Genitourinary Cancers Symposium. Read More ›

Adjuvant pembrolizumab (Key­truda) continued to provide a disease-free survival (DFS) benefit in patients with renal-cell carcinoma (RCC) at intermediate-high or high risk of recurrence after nephrectomy, according to 30-month follow-up data from the KEYNOTE-564 trial presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. Read More ›

The phase 3 CheckMate-816 trial establishes a new standard of care for resectable non–small-cell lung cancer (NSCLC): neoadjuvant nivolu­mab (Opdivo) plus chemotherapy. Read More ›

Page 1 of 2


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: